Global Hemoglobinopathies Drugs Market Professional Survey Report 2019

Table of Contents

Executive Summary

1 Industry Overview of Hemoglobinopathies Drugs

• 1.1 Definition of Hemoglobinopathies Drugs
• 1.2 Hemoglobinopathies Drugs Segment by Type
  • 1.2.1 Global Hemoglobinopathies Drugs Production Growth Rate Comparison by Types (2014-2025)
  • 1.2.2 Thalassemia Therapy
  • 1.2.3 Sickle Cell Disease(SCD) Therapy
  • 1.2.4 Other Therapy
• 1.3 Hemoglobinopathies Drugs Segment by Applications
  • 1.3.1 Global Hemoglobinopathies Drugs Consumption Comparison by Applications (2014-2025)
  • 1.3.2 Alpha Thalassemia
  • 1.3.3 Beta thalassemia
  • 1.3.4 Sickle Cell Disease
  • 1.3.5 Hb Variants Diseases
• 1.4 Global Hemoglobinopathies Drugs Overall Market
  • 1.4.1 Global Hemoglobinopathies Drugs Revenue (2014-2025)
  • 1.4.2 Global Hemoglobinopathies Drugs Production (2014-2025)
  • 1.4.3 North America Hemoglobinopathies Drugs Status and Prospect (2014-2025)
  • 1.4.4 Europe Hemoglobinopathies Drugs Status and Prospect (2014-2025)
  • 1.4.5 China Hemoglobinopathies Drugs Status and Prospect (2014-2025)
  • 1.4.6 Japan Hemoglobinopathies Drugs Status and Prospect (2014-2025)
  • 1.4.7 Southeast Asia Hemoglobinopathies Drugs Status and Prospect (2014-2025)
  • 1.4.8 India Hemoglobinopathies Drugs Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis

• 2.1 Raw Material and Suppliers
• 2.2 Manufacturing Cost Structure Analysis of Hemoglobinopathies Drugs
• 2.3 Manufacturing Process Analysis of Hemoglobinopathies Drugs
• 2.4 Industry Chain Structure of Hemoglobinopathies Drugs

3 Development and Manufacturing Plants Analysis of Hemoglobinopathies Drugs

• 3.1 Capacity and Commercial Production Date
• 3.2 Global Hemoglobinopathies Drugs Manufacturing Plants Distribution
• 3.3 Major Manufacturers Technology Source and Market Position of Hemoglobinopathies Drugs
• 3.4 Recent Development and Expansion Plans

4 Key Figures of Major Manufacturers

• 4.1 Hemoglobinopathies Drugs Production and Capacity Analysis
• 4.2 Hemoglobinopathies Drugs Revenue Analysis
• 4.3 Hemoglobinopathies Drugs Price Analysis
• 4.4 Market Concentration Degree

5 Hemoglobinopathies Drugs Regional Market Analysis

• 5.1 Hemoglobinopathies Drugs Production by Regions
  • 5.1.1 Global Hemoglobinopathies Drugs Production by Regions
  • 5.1.2 Global Hemoglobinopathies Drugs Revenue by Regions
• 5.2 Hemoglobinopathies Drugs Consumption by Regions
• 5.3 North America Hemoglobinopathies Drugs Market Analysis
  • 5.3.1 North America Hemoglobinopathies Drugs Production
  • 5.3.2 North America Hemoglobinopathies Drugs Revenue
  • 5.3.3 Key Manufacturers in North America
  • 5.3.4 North America Hemoglobinopathies Drugs Import and Export
• 5.4 Europe Hemoglobinopathies Drugs Market Analysis
  • 5.4.1 Europe Hemoglobinopathies Drugs Production
  • 5.4.2 Europe Hemoglobinopathies Drugs Revenue
  • 5.4.3 Key Manufacturers in Europe
  • 5.4.4 Europe Hemoglobinopathies Drugs Import and Export
• 5.5 China Hemoglobinopathies Drugs Market Analysis
  • 5.5.1 China Hemoglobinopathies Drugs Production
  • 5.5.2 China Hemoglobinopathies Drugs Revenue
  • 5.5.3 Key Manufacturers in China
  • 5.5.4 China Hemoglobinopathies Drugs Import and Export
• 5.6 Japan Hemoglobinopathies Drugs Market Analysis
  • 5.6.1 Japan Hemoglobinopathies Drugs Production
  • 5.6.2 Japan Hemoglobinopathies Drugs Revenue
  • 5.6.3 Key Manufacturers in Japan
  • 5.6.4 Japan Hemoglobinopathies Drugs Import and Export
• 5.7 Southeast Asia Hemoglobinopathies Drugs Market Analysis
  • 5.7.1 Southeast Asia Hemoglobinopathies Drugs Production
  • 5.7.2 Southeast Asia Hemoglobinopathies Drugs Revenue
  • 5.7.3 Key Manufacturers in Southeast Asia
  • 5.7.4 Southeast Asia Hemoglobinopathies Drugs Import and Export
• 5.8 India Hemoglobinopathies Drugs Market Analysis
  • 5.8.1 India Hemoglobinopathies Drugs Production
  • 5.8.2 India Hemoglobinopathies Drugs Revenue
  • 5.8.3 Key Manufacturers in India
  • 5.8.4 India Hemoglobinopathies Drugs Import and Export

6 Hemoglobinopathies Drugs Segment Market Analysis (by Type)

• 6.1 Global Hemoglobinopathies Drugs Production by Type
• 6.2 Global Hemoglobinopathies Drugs Revenue by Type
• 6.3 Hemoglobinopathies Drugs Price by Type

7 Hemoglobinopathies Drugs Segment Market Analysis (by Application)

• 7.1 Global Hemoglobinopathies Drugs Consumption by Application
• 7.2 Global Hemoglobinopathies Drugs Consumption Market Share by Application (2014-2019)

8 Hemoglobinopathies Drugs Major Manufacturers Analysis

• 8.1 Gamida Cell
  • 8.1.1 Gamida Cell Hemoglobinopathies Drugs Production Sites and Area Served
  • 8.1.2 Gamida Cell Product Introduction, Application and Specification
  • 8.1.3 Gamida Cell Hemoglobinopathies Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.1.4 Main Business and Markets Served
• 8.2 Alnylam Pharmaceuticals
  • 8.2.1 Alnylam Pharmaceuticals Hemoglobinopathies Drugs Production Sites and Area Served
  • 8.2.2 Alnylam Pharmaceuticals Product Introduction, Application and Specification
  • 8.2.3 Alnylam Pharmaceuticals Hemoglobinopathies Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.2.4 Main Business and Markets Served
• 8.3 Biogen Idec
  • 8.3.1 Biogen Idec Hemoglobinopathies Drugs Production Sites and Area Served
  • 8.3.2 Biogen Idec Product Introduction, Application and Specification
  • 8.3.3 Biogen Idec Hemoglobinopathies Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.3.4 Main Business and Markets Served
• 8.4 Sangamo BioSciences Inc.
  • 8.4.1 Sangamo BioSciences Inc. Hemoglobinopathies Drugs Production Sites and Area Served
  • 8.4.2 Sangamo BioSciences Inc. Product Introduction, Application and Specification
  • 8.4.3 Sangamo BioSciences Inc. Hemoglobinopathies Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.4.4 Main Business and Markets Served
• 8.5 Genetix Pharmaceuticals/Bluebird Bio
  • 8.5.1 Genetix Pharmaceuticals/Bluebird Bio Hemoglobinopathies Drugs Production Sites and Area Served
  • 8.5.2 Genetix Pharmaceuticals/Bluebird Bio Product Introduction, Application and Specification
  • 8.5.3 Genetix Pharmaceuticals/Bluebird Bio Hemoglobinopathies Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.5.4 Main Business and Markets Served
• 8.6 Global Blood Therapeutics Inc.
  • 8.6.1 Global Blood Therapeutics Inc. Hemoglobinopathies Drugs Production Sites and Area Served
  • 8.6.2 Global Blood Therapeutics Inc. Product Introduction, Application and Specification
  • 8.6.3 Global Blood Therapeutics Inc. Hemoglobinopathies Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.6.4 Main Business and Markets Served
• 8.7 Pfizer Inc.
  • 8.7.1 Pfizer Inc. Hemoglobinopathies Drugs Production Sites and Area Served
  • 8.7.2 Pfizer Inc. Product Introduction, Application and Specification
  • 8.7.3 Pfizer Inc. Hemoglobinopathies Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.7.4 Main Business and Markets Served
• 8.8 Mast Therapeutics
  • 8.8.1 Mast Therapeutics Hemoglobinopathies Drugs Production Sites and Area Served
  • 8.8.2 Mast Therapeutics Product Introduction, Application and Specification
  • 8.8.3 Mast Therapeutics Hemoglobinopathies Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.8.4 Main Business and Markets Served
• 8.9 Emmaus Life Sciences, Inc.
  • 8.9.1 Emmaus Life Sciences, Inc. Hemoglobinopathies Drugs Production Sites and Area Served
  • 8.9.2 Emmaus Life Sciences, Inc. Product Introduction, Application and Specification
  • 8.9.3 Emmaus Life Sciences, Inc. Hemoglobinopathies Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.9.4 Main Business and Markets Served
• 8.10 Prolong Pharmaceuticals
  • 8.10.1 Prolong Pharmaceuticals Hemoglobinopathies Drugs Production Sites and Area Served
  • 8.10.2 Prolong Pharmaceuticals Product Introduction, Application and Specification
  • 8.10.3 Prolong Pharmaceuticals Hemoglobinopathies Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.10.4 Main Business and Markets Served
• 8.11 Celgene Corporation
• 8.12 HemaQuest Pharmaceuticals

9 Development Trend of Analysis of Hemoglobinopathies Drugs Market

• 9.1 Global Hemoglobinopathies Drugs Market Trend Analysis
  • 9.1.1 Global Hemoglobinopathies Drugs Market Size (Volume and Value) Forecast 2019-2025
• 9.2 Hemoglobinopathies Drugs Regional Market Trend
  • 9.2.1 North America Hemoglobinopathies Drugs Forecast 2019-2025
  • 9.2.2 Europe Hemoglobinopathies Drugs Forecast 2019-2025
  • 9.2.3 China Hemoglobinopathies Drugs Forecast 2019-2025
  • 9.2.4 Japan Hemoglobinopathies Drugs Forecast 2019-2025
  • 9.2.5 Southeast Asia Hemoglobinopathies Drugs Forecast 2019-2025
  • 9.2.6 India Hemoglobinopathies Drugs Forecast 2019-2025
• 9.3 Hemoglobinopathies Drugs Market Trend (Product Type)
• 9.4 Hemoglobinopathies Drugs Market Trend (Application)
• 10.1 Marketing Channel
  • 10.1.1 Direct Marketing
  • 10.1.2 Indirect Marketing
• 10.3 Hemoglobinopathies Drugs Customers

11 Market Dynamics

• 11.1 Market Trends
• 11.2 Opportunities
• 11.3 Market Drivers
• 11.4 Challenges
• 11.5 Influence Factors

12 Conclusion

13 Appendix

• 13.1 Methodology/Research Approach
  • 13.1.1 Research Programs/Design
  • 13.1.2 Market Size Estimation
  • 13.1.3 Market Breakdown and Data Triangulation
• 13.2 Data Source
  • 13.2.1 Secondary Sources
  • 13.2.2 Primary Sources
• 13.3 Author List